The leading health risk for women is not breast cancer, though breast cancer receives the most public attention and fear. It is cardiovascular disease, which kills more women than all cancers combined. And yet the conversation about women’s cardiovascular health remains dangerously incomplete in the clinical context, particularly around the role that hormonal changes during midlife play in dramatically elevating that risk. Dr. Mary Claire Haver addresses this gap directly, and the implications for women in their 40s and 50s are significant.
Estrogen’s Protective Role in Cardiovascular Health
Before menopause, women have substantially lower rates of cardiovascular disease than men of the same age. That protective advantage is largely attributable to estrogen. Estrogen supports healthy LDL and HDL cholesterol levels, maintains arterial flexibility and endothelial function, reduces vascular inflammation, and supports healthy blood pressure regulation. When estrogen levels decline during perimenopause and menopause, these protective mechanisms diminish, and cardiovascular disease risk rises accordingly. Research shows that within years of menopause, women’s cardiovascular disease risk converges with and eventually exceeds that of men the same age.
The Full Cascade of Risks Associated with Hormonal Decline
Dr. Haver is specific about the range of chronic disease risks that increase with the hormonal transition of menopause: cardiovascular disease, type 2 diabetes, dementia and Alzheimer’s disease, osteoporosis, and certain cancers. These are not isolated, unrelated conditions. They share common upstream drivers in the hormonal and metabolic changes of menopause. Yet the standard annual women’s health appointment rarely engages with the connection between a woman’s hormonal status and her trajectory toward these conditions.
Why Women’s Heart Attacks Present Differently
Women are statistically more likely to experience atypical presentations of cardiac events, fatigue, shortness of breath, nausea, jaw pain, back pain, rather than the classic chest-pressure presentation more commonly depicted and discussed. These symptoms are easier to attribute to other causes, delay recognition, and result in delayed treatment. Awareness of atypical cardiac symptoms in women is genuinely life-saving information that is not widely communicated.
Menopause Is a Whole-Body Transition
Dr. Haver’s most important contribution to this conversation is her insistence on reframing menopause as a systemic, whole-body metabolic and hormonal transition rather than a reproductive event. The effects of declining estrogen are felt in the brain, the cardiovascular system, the skeletal system, the metabolic system, the skin, and the gastrointestinal tract simultaneously. Managing this transition with informed medical support is not about comfort, it is a disease prevention strategy with documented long-term health implications.
Conversations Worth Having With Your Provider
At your next annual appointment, consider asking specifically about cardiovascular risk in the context of your hormonal status. Ask about trends in your lipid panel over time, blood pressure trajectory, fasting insulin, and blood glucose. Ask whether hormone therapy is appropriate for you and what the evidence says about its cardiovascular effects when initiated in the appropriate window after menopause. If your provider is not engaging substantively with these questions, seeking a menopause-informed physician is a worthwhile investment in your long-term health.
The information gap around women’s cardiovascular health and menopause is closing, but not quickly enough. Knowing the connection exists puts you in a position to ask better questions, seek better care, and make better decisions.
RESOURCE:
Watch the full conversation with Dr. Mary Claire Haver on The Diary of a CEO with Steven Bartlett:
The Impact of Menopause on Women’s Health | Dr. Mary Claire Haver | The Diary Of A CEO